Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IDEAYA Biosciences (IDYA) EBT Margin: 2020-2025

Historic EBT Margin for IDEAYA Biosciences (IDYA) over the last 3 years, with Sep 2025 value amounting to 52.18%.

  • IDEAYA Biosciences' EBT Margin was N/A to 52.18% in Q3 2025 from the same period last year, while for Sep 2025 it was -73.86%, marking a year-over-year change of. This contributed to the annual value of -4,671.07% for FY2024, which is 409622.00% down from last year.
  • As of Q3 2025, IDEAYA Biosciences' EBT Margin stood at 52.18%, which was up 102.53% from -2,059.11% recorded in Q4 2024.
  • IDEAYA Biosciences' EBT Margin's 5-year high stood at 52.18% during Q3 2025, with a 5-year trough of -2,059.11% in Q4 2024.
  • Its 3-year average for EBT Margin is -791.54%, with a median of -670.02% in 2023.
  • As far as peak fluctuations go, IDEAYA Biosciences' EBT Margin spiked by 13,271bps in 2022, and later slumped by 99,035bps in 2024.
  • Over the past 5 years, IDEAYA Biosciences' EBT Margin (Quarterly) stood at -620.16% in 2021, then plummeted by 3,730bps to -657.46% in 2022, then crashed by 41,131bps to -1,068.77% in 2023, then slumped by 99,035bps to -2,059.11% in 2024, then reached 52.18% in 2025.
  • Its EBT Margin was 52.18% in Q3 2025, compared to -2,059.11% in Q4 2024 and -1,068.77% in Q4 2023.